Scientific deep-dive
BPC-157 vs TB-500: Recovery Peptides Compared
BPC-157 and TB-500 are both marketed for recovery, but neither has a completed human RCT. TB-500 is a fragment of thymosin beta-4, not the pharmaceutical studied in trials. Both are WADA-prohibited.
Two peptides dominate the gray-market “recovery” space: BPC-157, a synthetic 15-amino-acid fragment of a protein found in human gastric juice, and TB-500, a short synthetic peptide sold as a functional analog of thymosin β4. Both are marketed aggressively — often as a stack — to athletes, bodybuilders, and anyone chasing faster tendon, muscle, or ligament repair. The honest evidence picture is far shorter than the marketing suggests: neither compound has a completed human randomized controlled trial showing it causes the recovery benefits sellers claim[1][2]; virtually all BPC-157 research is in rats[3]; and the TB-500 sold online is a truncated fragment chemically distinct from the pharmaceutical thymosin β4 that has reached Phase-I human safety trials[4][5]. Both are prohibited by the World Anti-Doping Agency and neither is FDA-approved for any human use. This article compares the two compounds honestly — what each actually is, what the animal literature shows, where the human evidence gap lies, and what the regulatory reality is. It is an evidence review and safety resource, not a dosing or sourcing guide. Status as of October 2026: in a draft policy, HHS says it does not intend to bring enforcement action against a 503A pharmacy that compounds either peptide on its own, as a single-ingredient product, and meets ten conditions. TB-500 acetate is limited to subcutaneous or intramuscular injection; BPC-157 acetate may also be given orally or topically[9]. The Federal Register notice calls it a draft, non-binding policy with a two-week comment window, not a rule[10]. See our explainer on the HHS 503A peptide policy and news report, plus the BPC-157 and TB-500 provider pages.
Side-by-side comparison
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic 15-amino-acid peptide derived from a fragment of human gastric BPC protein | Synthetic peptide based on the actin-binding domain of thymosin β4 (residues 17–23); sold as a functional analog[4][5] |
| Preclinical mechanism studied | Cytoprotection, angiogenesis, gut-mucosal protection, tendon and ligament healing in rats[3] | Actin sequestration, cell migration, angiogenesis, wound closure, cardiac protection — all in animal models[8] |
| Strongest studied use (animal) | Tendon, ligament, gut, and tissue repair in rodent injury models | Wound healing, ischemia protection, and cardiac repair in rodent and porcine models |
| Completed human RCT proving recovery? | None. No human randomized trial of musculoskeletal or athletic recovery[1][2] | None. TB-500 (the sold fragment) has no published human trial of any kind[1][4] |
| Human safety data | No completed human study of any design published in PubMed[2] | Phase-I safety data exists for full-length thymosin β4 (not TB-500 itself)[6][7] — the fragment sold online is different |
| WADA status | Prohibited — listed under S2 (Peptide Hormones, Growth Factors & Related Substances) | Prohibited — thymosin β4 and its analogs/fragments are banned under S2 |
| FDA status | Not approved. FDA Category 2 Sept 2023 to April 22, 2026; single-ingredient 503A compounding (SC, IM, oral, topical) under draft, interim HHS enforcement discretion since Oct 28, 2026[9] | Not approved. FDA Category 2 Sept 29, 2023 to April 22, 2026; single-ingredient 503A compounding (SC or IM) under draft, interim HHS enforcement discretion since Oct 28, 2026[9] |
| How it is sold | Mostly gray-market lyophilized powder, labeled “for research use only, not for human consumption”; since Oct 2026 also as a prescribed 503A compounded product | Mostly gray-market lyophilized powder with same research-use-only labeling; since Oct 2026 also as a prescribed 503A compounded injection |
BPC-157: what the evidence actually shows
BPC-157 (“Body Protection Compound-157”) is a pentadecapeptide — a chain of 15 amino acids — synthesized from a partial sequence of the human gastric protein BPC. Its appeal in the sports and anti-aging community stems from a large rodent literature showing that it accelerates tendon, ligament, bone, gut mucosa, and wound healing in animal injury models, apparently through effects on angiogenesis (new blood vessel formation) and cytoprotection[3]. A 2026 review by Sikiric and colleagues summarizes these preclinical findings across hemorrhage, thrombosis, and tissue-repair models in rats — every study described is animal work[3].
The critical problem is the translation gap. A 2026 review specifically addressing BPC-157’s path toward human application — examining biopharmaceutical challenges and formulation barriers — documents that no completed human randomized controlled trial of BPC-157 for musculoskeletal recovery, athletic performance, or any injury indication has been published[2]. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance reached the same conclusion: BPC-157 lacks the clinical trial data needed to support routine human use[1]. Promising effects in rats fail to translate to humans far more often than they succeed, and BPC-157 has simply never been put through the human trials that would test whether the animal results hold.
TB-500: a peptide fragment, not the same as the pharmaceutical thymosin β4
Understanding TB-500 requires separating two related but distinct things: (1) thymosin β4 (Tβ4), the full 43-amino-acid endogenous protein with genuine pharmaceutical interest, and (2) TB-500, the truncated synthetic fragment actually sold in gray-market vials. TB-500 was characterized in 2012 by anti-doping laboratories as “the N-terminal acetylated 17–23 fragment of thymosin beta 4”[5] and is identified by doping-control researchers as “a synthetic version of an active region of thymosin β4”[4]. The fragment contains the sequence responsible for actin binding — thymosin β4’s ability to sequester G-actin and thereby influence cell motility, wound repair, and angiogenesis[8] — but it is not the same molecule as the full-length Tβ4.
Full-length thymosin β4 has reached Phase-I human safety trials. Ruff and colleagues conducted a randomized, placebo-controlled, single- and multiple-dose study of intravenous thymosin β4 in healthy volunteers and found no dose-limiting toxicities[6]. Wang and colleagues published a first-in-human, randomized, double-blind Phase-I study of recombinant human thymosin β4 in healthy Chinese volunteers, again demonstrating an acceptable short-term safety profile[7]. These studies established preliminary safety for full-length Tβ4. They say nothing about the safety or efficacy of the truncated TB-500 fragment sold online, which is a chemically distinct product that has undergone no published human trial of any design[1][4]. Sellers routinely use the Phase-I Tβ4 data to imply TB-500 is “clinically studied,” which is inaccurate. Our page on TB-500 side effects sets out what is and is not known about the fragment.
The translation gap is the finding, not a caveat
For health decisions like this, the absence of human evidence is itself the key fact. “No proof of harm” is not “proof of safety.” “Studied in rats” is not “proven in humans.” When you inject either of these compounds from a gray-market vial, no agency has verified the identity, purity, sterility, or actual dose of what you are injecting — and no human trial has shown the expected benefit will occur. These risks are unoffset by a proven benefit.
WADA prohibition and FDA status
Both compounds are prohibited in sport. The World Anti-Doping Agency lists thymosin β4 and its fragments and analogs — a category that explicitly encompasses TB-500 — as prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Anti-doping laboratories have developed validated LC-MS methods specifically to detect TB-500 in equine and human biological samples[4], and the compound is flagged as a doping risk in multiple forensic doping-control analyses[5]. BPC-157 is prohibited too, named under WADA’s S0 (non-approved substances). An athlete using either compound — in any context, including “therapeutic” self-administration — risks a positive anti-doping test, and no WADA-approved therapeutic use exemption exists for either.
From a US regulatory standpoint, neither is approved by the FDA for any human indication. There is no approved BPC-157 drug and no DailyMed listing for it, and no FDA-approved application exists for TB-500. Both were in FDA’s Category 2 of nominated bulk substances until April 22, 2026, with FDA’s drug center (CDER) recommending against listing them and the Pharmacy Compounding Advisory Committee voting in favor[9]. Since October 28, 2026, a draft and non-binding HHS policy has said HHS does not intend to bring enforcement action against 503A compounding of either one by itself, as long as there is a prescription for a specific patient and a certificate of analysis from a manufacturer registered with FDA. A premixed BPC-157 and TB-500 blend is not covered, and neither are 503B outsourcing facilities[9]. Most product is still sold as research chemicals with “not for human consumption” labeling, a disclaimer that sidesteps drug-marketing rules but is widely disregarded by buyers.
Can you stack BPC-157 and TB-500?
The marketing rationale for stacking the two peptides is that they allegedly work through complementary pathways: BPC-157 via gut-protective and tendon-healing effects, TB-500 via actin sequestration and angiogenesis. In theory these mechanisms could be additive in a rodent wound model. In practice: there is no published human study of either peptide alone for athletic recovery, and no published study — in animals or humans — of the two combined in humans. Any claim that stacking produces synergistic recovery in athletes is pure speculation without a clinical evidence base. Combining two compounds with unverified individual risk profiles in humans introduces compounded uncertainty, not compounded benefit.
Bottom line
BPC-157 and TB-500 represent a common category in the gray-market peptide space: compounds with genuine, interesting preclinical biology that have not been validated in human randomized controlled trials for the recovery benefits marketed to athletes and biohackers[1][2]. BPC-157 has a real rodent literature in tissue and gut healing, but no controlled human trial[2][3]. TB-500 is not the same molecule as the pharmaceutical thymosin β4 that reached Phase-I human safety testing — it is a truncated fragment with no human trial data of its own[4][5][6][7]. Both are WADA-prohibited and sold as unregulated research chemicals whose purity, identity, and dose are unverified by any agency. The enthusiasm of their online communities does not substitute for randomized clinical evidence. If you are seeking evidence-based recovery support, the options with human data are diet, progressive loading, sleep, and — for specific clinical indications — treatments approved after human clinical trials.
A PubMed search for completed human RCTs of BPC-157 or TB-500 proving athletic recovery returned zero results. Discuss any peptide use with a licensed healthcare provider.
Frequently Asked Questions
References
- 1.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. PMID: 41966639.
- 2.Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, Ilie AC, Folescu R, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026. PMID: 42198317.
- 3.Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, et al. Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics. Pharmaceuticals (Basel). 2026. PMID: 41901308.
- 4.Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PMID: 23084823.
- 5.Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PMID: 22962027.
- 6.Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PMID: 20536472.
- 7.Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021. PMID: 34346165.
- 8.Ying Y, Lin C, Tao N, Hoffman RD, Shi D, Chen Z, et al. Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications. Curr Protein Pept Sci. 2023. PMID: 36464872.
- 9.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and Appendix B). HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- 10.U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice; Docket No. HHS-OASH-2026-0496; FR Doc. 2026-22192. Federal Register. 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
Related research
Are Peptides Legal? 2026 Rules for Compounded vs Research Peptides
FDA-approved peptide drugs are legal by prescription. A draft October 2026 HHS policy says HHS does not intend to enforce against 503A compounding of six peptides, including BPC-157 and TB-500, under ten conditions. Research-chemical peptides are still not legal for human use.
12 min read
Wolverine Stack (BPC-157 + TB-500): Evidence, and Why Premixed Blends Aren't Covered
The Wolverine stack pairs BPC-157 and TB-500, and all efficacy data come from animal or lab studies; no human trial exists. A draft 2026 HHS policy would not enforce against single-ingredient 503A compounding of each peptide, but premixed blends are not covered. WADA bans both.
10 min read
KLOW Peptide Blend (KPV, GHK-Cu, BPC-157, TB-500): Evidence and Legal Status
What is in the KLOW peptide blend (GHK-Cu, BPC-157, TB-500, KPV), what the evidence shows for each, why there is no established dose, and why the draft 2026 HHS compounding policy does not cover blends or GHK-Cu.
9 min read
Peptide Stacking Safety: BPC-157 + TB-500, CJC-1295 + Ipamorelin
No human trial tests any peptide stack. Individual evidence for CJC-1295 and ipamorelin is thin; BPC-157 and TB-500 are near-evidence-free. Stacking multiplies risks, and WADA prohibits all four.
10 min read
BPC-157 Side Effects & Safety: What's Actually Known
BPC-157 safety review: what animal studies show, why only about 30 humans have been studied in uncontrolled pilots, gray-market and injection risks, the 2026 HHS compounding policy and its MedWatch reporting rule, and the WADA ban.
10 min read
How to Get a BPC-157 Prescription in 2026: 503A Pharmacy Steps and Red Flags
How to get BPC-157 online in 2026 under the draft HHS 503A policy: who can prescribe and compound it, the questions to ask a pharmacy (COA, single ingredient, label, syringe), research-chemical red flags, and what the evidence shows.
9 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →Pricing Compare
Get started →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →